References
- Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074–1080.
- De Ruijter MM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): charac-terization of the classical HDAC family. Biochem J 2003; 370: 737–749.
- Cheng HL, Mostoslavsky R, Saito S et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci 2003; 100: 10794–10799.
- Kelly WK, Richon VM, O'Connor O et al. Phase I clini-cal trial of histone deacetylase inhibitors: suberoylanilide hydroxamic acid administered intravenously. Clin Can Res 2003; 9: 3578–3588.
- Blaheta RA, Nau H, Michaelis M, Cinatlt Jr J. Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 2002; 9: 1417–1433.
- Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718–728.
- Saito A, Yamashita T, Mariko Y et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumour activity against human tumors. Proc Natl Acad Sci 1999; 96: 4592–4597.
- Prakash S, Foster BJ, Meyer M et al. Chronic oral administration of CI-994. Invest New Drugs 2001; 19: 1–11.
- McLaughlin F, Finn P, La Thangue NB. The cell cycle, chromatin and cancer: mechanism based therapeutics come of age. Drug Disc Today 2003; 8: 793–802.
- Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001; 11: 2363-2373.
- Glaser KB, Stayer MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple his-tone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2: 151–163.
- Yu C, Rahmani M, Almerara J, et al. Histone deacety-lase inhibitors promote 5T1571-mediated apoptosis in 5T1571-sensitive and -resistant Bcr/Abl+ Human Myeloid leukaemia cells. Cancer Res 2003; 63: 2118-2126.
- Nimmanapalli R, Fuino L, Stobaugh C, Richon VM, Bhalla K. Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells. Blood 2003; 101: 3236–3239.
- jang ER, Lim S-J, Lee ES, et al. The histone deacety-lase inhibitor trichostatin A sensitizes estrogen receptor a-neg-ative breast cancer cells to tamoxifen. Oncogene 2004; 23: 1724–1736.
- Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti-Canc Agents 2003; 3: 187–199.
- Hu E, Dul E, Sung CM et al. Identification of novel iso-form-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003; 2: 720–728.
- Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4616–4621.